Insider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Director Sells 8,212 Shares of Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Director Barry D. Quart sold 8,212 shares of Kiniksa Pharmaceuticals stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $30.36, for a total transaction of $249,316.32. Following the completion of the sale, the director now directly owns 12,546 shares in the company, valued at $380,896.56. This represents a 39.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Kiniksa Pharmaceuticals Stock Performance

Shares of KNSA stock opened at $28.30 on Friday. The stock’s fifty day moving average is $25.12 and its two-hundred day moving average is $22.17. The firm has a market capitalization of $2.07 billion, a P/E ratio of -202.13 and a beta of 0.06. Kiniksa Pharmaceuticals, Ltd. has a fifty-two week low of $17.38 and a fifty-two week high of $30.69.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The company had revenue of $137.79 million for the quarter, compared to analyst estimates of $128.35 million. During the same quarter last year, the firm posted ($0.25) EPS. The firm’s revenue for the quarter was up 72.5% on a year-over-year basis. On average, equities analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current year.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals

A number of hedge funds have recently modified their holdings of KNSA. Nuveen LLC purchased a new stake in shares of Kiniksa Pharmaceuticals in the first quarter valued at about $16,992,000. Acadian Asset Management LLC grew its holdings in shares of Kiniksa Pharmaceuticals by 170.3% in the first quarter. Acadian Asset Management LLC now owns 1,034,321 shares of the company’s stock valued at $22,961,000 after purchasing an additional 651,700 shares during the period. Braidwell LP grew its holdings in shares of Kiniksa Pharmaceuticals by 19.3% in the fourth quarter. Braidwell LP now owns 3,452,447 shares of the company’s stock valued at $68,289,000 after purchasing an additional 557,934 shares during the period. AQR Capital Management LLC grew its holdings in shares of Kiniksa Pharmaceuticals by 149.1% in the first quarter. AQR Capital Management LLC now owns 491,761 shares of the company’s stock valued at $10,922,000 after purchasing an additional 294,319 shares during the period. Finally, JPMorgan Chase & Co. grew its holdings in shares of Kiniksa Pharmaceuticals by 138.9% in the fourth quarter. JPMorgan Chase & Co. now owns 477,800 shares of the company’s stock valued at $9,451,000 after purchasing an additional 277,827 shares during the period. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on KNSA shares. Citigroup started coverage on shares of Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They issued a “buy” rating and a $40.00 price target on the stock. Jefferies Financial Group lifted their price target on shares of Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Tuesday, April 29th. Wall Street Zen raised shares of Kiniksa Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Wedbush reissued an “outperform” rating and issued a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research note on Wednesday, April 16th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $38.80.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.